Talzenna gains FDA approval for earlier-line HRR-mutated metastatic prostate cancer

On October 26, 2026, FDA approved Talzenna (talazoparib) in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer (mHSPC). Patients must have homologous recombination repair (HRR) gene mutations identified by an FDA-authorized test.

The approval moves the poly(ADP-ribose) polymerase (PARP) inhibitor combination into an earlier disease setting. Talzenna plus enzalutamide was approved in 2023 for HRR-mutated metastatic castration-resistant prostate cancer (mCRPC).

The decision was based on the phase 3 TALAPRO-3 trial, which enrolled 599 patients with HRR-mutated mHSPC. All patients received androgen deprivation therapy and were assigned to enzalutamide plus either talazoparib or placebo. Adding talazoparib to enzalutamide reduced the risk of radiographic progression or death by 52% compared with enzalutamide alone. Median radiographic progression-free survival was not reached with the combination, versus 45.8 months in the control arm. Overall survival data were immature at the time of analysis.

Clinical benefit was observed in patients with both BRCA and non-BRCA HRR gene alterations. An estimated 77% of patients remained free of radiographic progression at 3 years.

The safety profile was consistent with the known effects of each agent. Anemia was the most frequent grade 3 or higher treatment-emergent adverse event, occurring in 51% of patients receiving talazoparib versus 3% receiving placebo, and 5% discontinued talazoparib because of it. Prescribing information includes warnings for myelodysplastic syndrome/acute myeloid leukemia, myelosuppression, and embryo-fetal toxicity. Monthly blood-count monitoring is recommended, with dose modifications and supportive care used to manage hematologic toxicity when needed.

“This approval represents a critical advancement for patients with newly diagnosed metastatic prostate cancer with HRR gene mutations, who face a more aggressive disease, worse prognosis, and limited treatment options. In the TALAPRO-3 trial, clinical benefits were consistent for patients with BRCA and non-BRCA HRR gene mutations, addressing a long-standing unmet need – and reinforcing the importance of biomarker testing at the time of diagnosis,” said Neeraj Agarwal, MD, FASCO, global lead investigator for TALAPRO-3 and medical oncologist at Dana-Farber Cancer Institute.

Sources: FDA. (2026 Oct 26). FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations; Pfizer. (2026 Oct 26). Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting